Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quantum Biopharma ( (TSE:QNTM) ) just unveiled an update.
On October 2, 2025, Quantum BioPharma announced it received final reports for two key studies on its potential breakthrough drug, Lucid-MS, for multiple sclerosis. These reports are crucial for supporting an Investigational New Drug application with the US FDA, moving the company closer to initiating a Phase 2 clinical trial. This development marks a significant milestone in Quantum BioPharma’s efforts to position Lucid-MS as a first-in-class treatment for MS, potentially enhancing its market presence and offering new hope for stakeholders involved in MS treatment.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals Inc., is advancing its lead compound, Lucid-MS, which targets myelin degradation in multiple sclerosis. Quantum BioPharma also holds strategic investments and retains a stake in Unbuzzd Wellness Inc., which markets the OTC product unbuzzd.
Average Trading Volume: 3,695
Technical Sentiment Signal: Buy
Current Market Cap: C$89.48M
See more data about QNTM stock on TipRanks’ Stock Analysis page.